Introduction
Neutrophil production is critically regulated by granulocyte colony-stimulating factor (G-CSF) and its cognate receptor (G-CSFR) (1, 2) . The G-CSFR is a type I cytokine receptor that contains an extracellular domain with a conserved ligand binding region, a single transmembrane domain, and a cytoplasmic tail. The extracellular portion contains an N-terminal Ig-like domain, a cytokine receptor homology (CRH) domain, and three fibronectin type III (FNIII) domains (3) .
Within the CRH region are two FNIII domains, four conserved cysteine residues, and a conserved WSXWS motif that stabilizes the CRH domain (4, 5) . The Ig-like and CRH domains appear to be critical for high affinity binding (6, 7) .
The cytoplasmic tail of the G-CSFR is not required for ligand binding but is essential for signal transduction (6, (8) (9) (10) . Like other members of the cytokine receptor superfamily, the cytoplasmic portion of the G-CSFR lacks intrinsic kinase activity yet activates Janus tyrosine kinases (JAKs) following ligand binding. Jak kinase activation is believed to occur by ligandinduced receptor dimerization, which brings together G-CSFR-associated JAKs permitting their trans-phosphorylation. Following phosphorylation of JAKs, the G-CSFR itself is phosphorylated on cytoplasmic tyrosine residues and recruits downstream signaling molecules. Initiation of signaling culminates in myeloid cell proliferation, neutrophilic maturation, or activation of terminally differentiated neutrophils, which are modulated by a balance of positive and negative feedback signals (11) (12) (13) (14) (15) (16) (17) (18) (19) .
A maturation arrest of myeloid progenitors in the bone marrow at the promyelocyte/myelocyte stage and low peripheral blood neutrophil counts (ANC<200/mm 3 (21) (22) (23) . These mutations truncate the C-terminal tail that is required for growth arrest, differentiation signaling, and downmodulation of receptor expression, and produce a dominant negative phenotype both in vivo and in vitro that is postulated to be mediated by heterodimerization of wild-type (WT) and mutant G-CSFR forms (15, (23) (24) (25) . Rare patients with SCN refractory to G-CSF treatment have been reported, although the mechanisms underlying their unresponsiveness remain unclear (26, 27 ).
Here we report a novel truncation mutation in the extracellular domain of the G-CSFR in a patient with SCN unresponsive to G-CSF therapy. The mutation disrupts the WSXWS motif after the first tryptophan and localizes to the same region of the G-CSFR where mutations were identified in two previous patients with SCN who were also unresponsive to G-CSF. We show that the mutant G-CSFR form we have identified (designated ∆319) heterodimerizes with the WT G-CSFR and that the formation of WT/mutant G-CSFR heterodimers occurs independent of ligand binding. We also demonstrate that the mutant G-CSFR decreases the surface expression of the WT receptor and thereby inhibits proliferative signaling by the WT G-CSFR. These findings suggest a common mechanism underlying G-CSF refractoriness in patients with SCN, and also provide new insights into the basic mechanisms of G-CSFR processing and signaling.
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Materials and Methods

Reagents and cell culture
Neutrophils were purified from peripheral blood following appropriate informed consent using Ficoll-Hypaque centrifugation (p=1.077) and dextran sulfate sedimentation. Contaminating erythrocytes were removed by hypotonic lysis. Neutrophils used for all subsequent studies were >98% pure by Wright-Giemsa staining. Buccal cells and fibroblasts were obtained following appropriate informed consent. Fibroblasts were cultured in RPMI 1640 medium supplemented with 2 mM glutamine and 10% fetal bovine serum (FBS). BaF3 cells were maintained in RPMI 1640 medium supplemented with 2 mM glutamine, 10% FBS, and 10% WEHI-3B conditioned media as a source of IL-3. CHO cells were grown in αMEM media supplemented with 4.5 g/L glucose and 10% FBS. Penicillin and streptomycin (100 units/mL each) were added to all culture media. Recombinant human G-CSF was a generous gift from Amgen. Media and cell culture reagents were purchased from GIBCO/Invitrogen.
RT-PCR and genomic DNA analysis
Total RNA was purified with Trizol (Invitrogen) and subsequently incubated with Superscript II reverse transcriptase (Invitrogen) to generate cDNA. Genomic DNA was purified with DNAzol (Invitrogen). Using two primer pairs that amplify overlapping fragments corresponding to bp. 106-832 and bp. 772-1707 of the G-CSFR, the entire extracellular portion of the human G-CSFR was amplified as previously described (26) . The resultant amplification products were visualized on 1% agarose/TAE gels and cloned into the pCR4-Blunt TOPO vector (Invitrogen) for sequencing. For detection of the ∆319 GHOHWLRQLQJHQRPLF'1$WKHSULPHUV hGR808F: 5'-ACAAGCCGCAGCGTGGAGAAG-3' and hGR1206R: 5'-only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From TTCTGAAGGCAGGTGGAAGGTG-3' were used. T he latter primer pair amplifies a fragment between exons 7 and 10 of the human G-CSFR gene and produces products from genomic DNA of 1039 bp and 332 bp corresponding to the WT and ∆319 G-CSFR forms, respectively. When cDNA is used as a template with the hGR808F/hGR1206R primer pair, amplification products of 398 bp and 207 bp are generated from the WT and ∆319 G-CSFR forms, respectively.
Plasmid construction and transfection
The entire open reading frame of the WT G-CSFR was amplified using Advantage-HF2 DNA polymerase (Clonetech) and cloned into the pcDNA3.1D-TOPO mammalian expression vector (Invitrogen). PCR reactions were performed with an initial 3 min denaturation at 94°C, followed by 25 cycles of denaturation at 94°C for 30s, annealing at 63°C for 30s, elongation at 68°C for 90s, and a final 3 min elongation at 68°C. The forward primer used for amplification contained a Kozak consensus sequence (28) (5' -CACCATGGCAAGGCTGGGAAACTGC-3') and the reverse primer (5' -GAAGCTCCCCAGCGCCTCCATC-3') lacked a stop codon to allow read through to the V5 and His6 epitope tags contained within the vector sequence. The WT G-CSFR was epitope-tagged with V5 and His6 (pcDNA3.1D/WTv5h6). For generation of the Myc-tagged ∆319 G-CSFR construct (pcDNA3.1D/∆319+myc), the same forward primer but a different reverse primer (5' -TCACAGATCCTCTTCTGAGATGAGTTTTTGTTCTAGGCCACAAGGGCCAC-3' were used in PCR reactions. For these reactions, the first five cycles were carried out under the identical conditions used for amplification of the WT G-CSFR, but for the last twenty cycles denaturation was done at 94°C for 30s, which was followed by a combined annealing/elongation stably transfected with the various G-CSFR forms using conditions that have previously been described (29) . Single clones were isolated by limiting dilution and screened by immunoblotting.
Immunoprecipitation and immunoblot analysis
Cells (2x10 7 /mL) were lysed in lysis buffer (1.5% triton X-100, 0.1% SDS, 0.1 mM sodium deoxycholate, 500 mM NaCl, 5 mM EDTA, 25 mM HEPES, pH 7.8) containing a cocktail of protease inhibitors (Roche), incubated on ice for 20 minutes, and centrifuged at 4°C at 10,000 x g. The supernatants were collected from each sample and the protein concentrations determined using the BCA reagent (Pierce 
Fluorescent Microscopy
Stably transfected CHO cells (7.5 x 10 4 ) were grown on glass cover slips for 24 hours at 37°C. The adherent cells were then washed with PBS, fixed in 3% paraformaldehyde for 1 hour, and incubated with PBS containing 0.1% sodium azide and 5% BSA for 1 hour at RT. The cells only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From were then incubated with a rabbit polyclonal anti-G-CSFR antibody (Santa Cruz sc9173) overnight at 4°C, washed with PBS containing 0.1% sodium azide, and incubated for 1 hour with Alexa-633-conjugated anti-rabbit secondary antibody (Molecular Probes). Nuclei were stained with Hoechst stain (Molecular Probes) for 15 min at RT. The cover slips containing the adherent cells were mounted on glass slides using Pro-Long Antifade mounting media (Molecular Probes) and examined under a Zeiss LSM 510 multiphoton confocal immunofluorescence microscope.
Results
Patient Data
A one-month old female infant presented with multiple abscesses, an ANC<200/mm3, and a normal hemoglobin and platelet count. Both parents were asymptomatic, and there was no family history of neutropenia. Autoimmune, genetic, and viral etiologies as well as PNH and introduction of an additional 29 missense codons followed by a premature stop codon. The mutation generates a truncated G-CSFR form containing the first 318 amino acids of the WT G-CSFR followed by the missense amino acids ( Figure 1B) . The truncated receptor, which we designated ∆319, retains the portion of the G-CSFR implicated in ligand-binding (30) (31) (32) , but disrupts the WSXWS motif, the three distal FNIII domains, the transmembrane domain, and all of the cytoplasmic domain.
Analysis of patient and parental cells.
To determine whether the ∆319 mutation, which we detected in approximately 50% of the clones generated by RT-PCR from the patient, was inherited and affected other cell lineages only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From in the patient, we examined genomic DNA (gDNA) from both parents as well as gDNA from non-hematopoietic cells (dermal fibroblasts) from the patient. To screen gDNA for the ∆319 mutation, we used the primer pair (hGR808F/hGR1206R) flanking the region deleted in the corresponding gDNA (Figure 2A) . This specific primer pair can be used to detect the ∆319 G-CSFR mutation in both cDNA and gDNA. As shown in Figure 2B , the mutation could only be detected in cDNA from the patient's PMN and was undetectable in genomic DNA from the patient's fibroblasts. The mutation was not detected in gDNA isolated fro m buccal cells, lymphocytes, and PMN from either parent, and only the WT G-CSFR form was detected in cDNA from PMN from either parent.
Subcellular localization of the ∆ ∆319 G-CSFR mutant
Since the ∆319 mutation removes the transmembrane portion of the G-CSFR, we were interested in determining whether the truncated receptor was secreted. We were unable to detect the mutant receptor in the patient's pre -transplant serum either by immunoprecipitation or immunoblotting (data not shown). Additionally, we could not detect the mutant receptor in conditioned media harvested from cells cotransfected with the WT and ∆319 G-CSFR forms, although it was highly expressed in whole cell lysates from the same cells ( Figure 3A) . To determine the subcellular distribution pattern of the ∆319 mutant, transfected cells were examined using confocal microscopy. For these studies, localization of the ∆319 G-CSFR was compared to the G-CSFR localization pattern in cells transfected with the ∆716 G-CSFR truncation mutant} ZKLFKZHKDYHSUHYLRXVO\ VKRZQWREHH[SUHVVHGDWKLJKOHYHOVDWWKHFHOO surface (15) . As shown in Figure 3B , the ∆319 G-CSFR truncation mutant was undetectable at only.
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Ligand-independent heterodimerization of the ∆ ∆319 mutant G-CSFR with the WT G-CSFR.
Since we were unable to demonstrate the presence of the ∆319 G-CSFR mutant at the cell surface to explain the dominant negative phenotype observed when both the ∆319 and WT G-CSFR forms are co-expressed, we hypothesized that the truncated receptor might interact intracellularly with the WT receptor in order to alter its function. To investigate whether 
Co-expression of the WT G-CSFR with the ∆ ∆319 mutant abrogates G-CSF-stimulated proliferative signaling by the WT G-CSFR and reduces its surface expression
In order to investigate the biological consequences of co-expression of the ∆319 G-CSFR along with the WT G-CSFR, we examined the proliferation of BaF3 transfectants in response to G-CSF. The growth curves for BaF3 cells stably expressing the WT G-CSFR only, the ∆319 G-CSFR only, or co-expressing both the WT and ∆319 G-CSFR forms are shown in Mutations in the extracellular region of the G-CSFR have also been reported in two patients with SCN without AML. Both patients had severe neutropenia that was diagnosed early in life and both patients were unresponsive to G-CSF therapy (26, 27) . Despite these important observations, the mechanisms by which these mutations induce the neutropenic phenotype remain largely unknown.
Although G-CSFR mutations are generally thought not to be causative of SCN, their role in SCN remains unclear. The frequent association of G-CSFR mutations with transformation to AML in patients with SCN has led to the hypothesis that these mutations contribute to leukemogenesis, although G-CSFR mutations do not invariantly occur in AML and may also appear in the absence of neoplasia (36) . Notably, receptor mutations in SCN/AML localize to the cytoplasmic region of the G-CSFR.
The ∆319 G-CSFR mutation identified in our patient disrupts the WSXWS motif and deletes the extracellular portion distal to the first tryptophan and the entire transmembrane and cytoplasmic domains. Expression of this mutant in BaF3 cells, either alone or in combination with the WT G-CSFR, reproduces the dominant-negative phenotype observed in our patient. Our data provide further evidence for the relevance of mutations in the extracellular portion of the G- Thus, the ∆319 G-CSFR truncation mutant does not appear to confer G-CSF insensitivity by functioning as a soluble sink for G-CSF. We demonstrate that even when the WT G-CSFR is coexpressed along with the ∆319 mutant, the mutant receptor remains undetectable at the cell surface, indicating that the mutant receptor does not function to alter the affinity for ligand binding. Furthermore, using flow cytometry, we show that co-expression of the ∆319 mutant along with the WT G-CSFR decreases the surface expression of the WT receptor.
We also directly demonstrate that the truncated ∆319 G-CSFR forms oligomers in vivo with the WT G-CSFR in the absence of ligand to inhibit signaling by the WT G-CSFR. The intensity of growth inhibition quantitatively correlated with the level of expression of the mutant receptor form so that greater inhibition was observed as the level of expression of the ∆319 mutant relative to the WT G-CSFR increased. Collectively, our data support a model in which both the WT and mutant G-CSFR forms are transcribed and oligomerize during intracellular processing. Interaction of the WT G-CSFR with the ∆319 mutant leads to accumulation of the heterodimeric complexes intracellularly disrupting transport of the G-CSFR to the cell surface.
As a result, insufficient signals are generated to sustain G-CSFR-induced survival, growth, and/or differentiation.
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Similar defects in receptor processing and assembly have been reported with truncation mutants of the erythropoietin receptor (EpoR) (37) . Using a series of EpoR truncation mutants terminating either just before the first tryptophan of the WSXWS motif or immediately distal to the last serine of the motif, or nine amino acids after WSXWS motif, in which the transmembrane domain was also deleted, Miura et al. demonstrated that only the mutant terminating nine amino acids after the WSXWS motif, was secreted. Additionally, these investigators showed that all three truncated EpoR forms could constitutively associate with the WT receptor in a ligand-independent manner. Like the EpoR (37, 38) , our data also demonstrate a requirement for the WSXWS motif and/or sequences following it for correct sorting of the G-CSFR to the plasma membrane but not for constitutive receptor oligomerization. The WSXWS motif has also been shown to be important in protein folding for receptors for IL-2Rb (39) The location of any putative sorting signal/domain in the G-CSFR must lie between the WSXWS motif and the transmembrane domain, since expression of the entire extracellular portion of the G-CSFR produces a protein that is secreted (49) 
Fukunaga et al. using deletion analysis has indicated that the three FNIII domains proximal to the transmembrane domain are important for correct expression of the G-CSFR (6). Thus, for both the EpoR and the G-CSFR, sequences in the extracellular domain appear to be critical for correct expression and sorting of the mature receptor complexes to the plasma membrane.
Additionally, both receptors form oligomeric complexes, most likely dimers, during processing and transit of the receptor complexes to the plasma membrane.
Traditional dogma has held that the stimulus for cytokine receptor-induced signal transduction is ligand binding, which induces subsequent dimerization or oligomerization of receptor monomers. However, our data along with the increasing body of evidence with other cytokine receptors support a mechanism whereby ligand binding produces a conformational change in a preformed receptor dimer (or oligomer), and it is the conformational change itself that activates signal transduction (50) . Both crystallographic and biochemical data indicate that, indeed, activation of the EpoR results from conformational changes in preformed receptor dimers following ligand binding (51, 52) . The existence of preformed receptor dimers has been reported for a number of other surface receptors (53) (54) (55) (56) (57) . In the current paper, we show that the truncated ∆319 G-CSFR forms ligand-independent oligomers likely either in the ER or the Golgi. We have obtained similar results with the ∆716 G-CSFR mutant isolated from patients with SCN/AML, in which the distal cytoplasmic tail of the G-CSFR is deleted (manuscript in preparation). On the basis of these results, we hypothesize that the G-CSFR forms constitutive homodimers during processing and transit to the plasma membrane. Such a mechanism in which preformed dimers already exist at the cell membrane would permit more rapid activation of the signaling cascade upon ligand binding. There is evidence from earlier studies by Horan et al. that, indeed, the unligated G-CSFR can form dimers, albeit weakly (49, 58) , and that binding of only.
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Notably, the two previously reported patients with SCN with mutations localizing to the extracellular region of the G-CSFR were both unresponsive to treatment with G-CSF. The 
